The FDA has approved Lumvoa™ (veligrotug‑vvze), the first therapy with clinical evidence in both active and chronic thyroid eye disease, offering patients earlier relief from eye bulging and double vision.
Written By: Shaik Yasmeen, PharmD
Reviewed By: Pharmacally Editorial Team
The U.S. Food and Drug Administration (FDA) has approved Lumvoa™ (veligrotug-vvze) for the treatment of thyroid eye disease (TED), making it the first approved therapy with labeling supported by clinical data in both active and chronic TED. Developed by Viridian Therapeutics, Lumvoa is also the company’s first FDA-approved medicine and commercial product. The company plans an immediate commercial launch, enabling physicians to begin prescribing the therapy without delay.
About Thyroid Eye Disease
Thyroid eye disease is a rare autoimmune disorder characterized by inflammation and swelling of tissues around the eyes. Patients may experience proptosis (eye bulging), diplopia (double vision), pain, redness, swelling, and vision impairment, significantly affecting daily activities and quality of life. TED can occur in both active inflammatory and chronic fibrotic stages.
Phase 3 Clinical Evidence
The FDA approval was granted under Priority Review based on the pivotal THRIVE trial in active TED (NCT05176639) and THRIVE-2 in chronic TED (NCT06021054).
Both phase 3 studies met their primary endpoint and all secondary endpoints, demonstrating statistically significant and clinically meaningful improvements in the major signs and symptoms of TED by Week 15. Across both trials, Lumvoa produced rapid reductions in proptosis as early as three weeks after treatment initiation.
Lumvoa is the first FDA-approved therapy for TED to demonstrate statistically significant improvements in both diplopia response and complete resolution of diplopia in patients with active and chronic disease. The treatment also previously received Breakthrough Therapy Designation from the FDA.
About Lumvoa
Lumvoa is a fully antagonistic insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody that targets a key pathway involved in the inflammation and tissue remodeling associated with TED. The treatment is administered as five intravenous infusions over 12 weeks, with one infusion every three weeks.
Immediate Launch and Patient Support
Viridian announced that Lumvoa will be available immediately following approval. To support patient access, the company has launched ViridianCares™, a comprehensive patient support program offering insurance benefit verification, patient access assistance, and financial support programs for eligible patients.
Clinical Significance
Steve Mahoney, President and Chief Executive Officer of Viridian Therapeutics, said the approval represents an important milestone for both patients and the company, reflecting years of development and commercial preparation to ensure immediate access following approval.
Michael Yen, MD, Professor of Oculoplastic Surgery and Ophthalmology at Baylor College of Medicine and an investigator in the THRIVE program, said the clinical data demonstrated meaningful improvements across the full spectrum of TED, including rapid reductions in proptosis and significant improvements in diplopia.
Christine Gustafson, Founder and Executive Director of the TED Community Organization, welcomed the approval, noting that a new treatment option could benefit many patients living with the physical and emotional burden of thyroid eye disease.
Development Pipeline
The approval establishes Lumvoa as the first FDA-approved treatment with clinical evidence spanning both active and chronic TED and marks Viridian’s transition into a commercial-stage biotechnology company. The company is also advancing its subcutaneous IGF-1R antibody elegrobart, with a biologics license application (BLA) submission planned for the first quarter of 2027.
What This Means for Patients
The FDA approval of Lumvoa introduces the first therapy shown to be effective in both active and chronic thyroid eye disease. For patients, this means there is now a treatment option supported by clinical evidence that can address common symptoms such as eye bulging and double vision. Improvements were observed in trials within weeks of starting therapy, which may help patients regain clearer vision and reduce discomfort.
Having an FDA‑approved therapy also provides reassurance that the medicine has undergone formal review for safety and effectiveness. With ViridianCares™ available to assist with insurance and access, physicians can begin prescribing without delay, helping patients receive treatment in a timely manner.
Reference
About the Writer
Shaik Yasmeen (LinkedIn) is a Pharm.D graduate with interests in clinical pharmacy, pharmacovigilance, and medical writing. She has gained experience through hospital clinical postings, patient case reviews, case presentations, and literature evaluation. Passionate about evidence-based healthcare, she is committed to creating accurate and engaging medical content while continuously expanding her professional knowledge.